18 / 22
Page 49
Notes:
Volume 2
Journal of Microbiology and Biotechnology Reports
Microbial Biotechnology 2018
September 17-18, 2018
Microbial Biotechnology & Vaccine Design
September 17-18, 2018 Lisbon, Portugal
5
th
World Congress on
Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage
through technological advances
Pierre A Morgon
Virometix, Switzerland
The vaccine segment is anticipated to be one of the fastest growing one of the healthcare industry and several leading firms have
stepped up vaccine investments in recent years. Unlike therapeutic agents, vaccines are administered to healthy individuals only
once or very infrequently during a life time. Vaccines generate well-documented positive externalities, yet their poor awareness and
acceptability among vaccine end-users may contribute to resurgence of transmissible diseases and consequently trigger governmental
interventions such as mandating vaccination. In addition to technical and clinical development per the highest quality standards,
bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of stakeholders along the
entire value chain and addressing their respective purchasing behavioral drivers. Against a backdrop of anti-vaccination buzz and
vaccine fatigue, successful global launch and sustainable usage of a vaccine requires the development of a multi-pronged strategy
addressing all aspects in relation to acceptability (e.g. the motivation to immunize despite the quasi-disappearance of the disease),
accessibility (e.g. supply chain services), availability (e.g. mechanisms ensuring reliability of supply) and affordability (e.g. tiered
pricing policy taking country differences in per capita income into account). Leveraging novel technological advances can positively
influence the ability to activate these levers successfully.
pm@mrgnadvisors.comShideh Fatehi
et al., J Microbio and Biotech Rept 2018, Volume 2